Figure 3
From: Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer
Istiratumab inhibits ligand driven proliferation of ovarian cancer cell lines. Ovarian cancer cells grown overnight in 4% FBS were treated with 50 nM IGF-1 (A) 10 nM HRG (B) with and without 1uM istiratumab in duplicate as indicated for 72 hours and proliferation was assessed via Cell Titer-Glo® Luminescent Cell Viability Assay. Significance was determined by two-way ANOVA using GraphPad Prism software (*p < 0.033, **p < 0.002, ***p < 0.001).
